Published in Semin Immunopathol on May 25, 2011
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst (2013) 3.07
Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology (2014) 2.30
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective. Cancer Res (2012) 1.48
Science gone translational: the OX40 agonist story. Immunol Rev (2011) 1.39
Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology (2014) 1.35
Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer. Clin Cancer Res (2012) 1.31
Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses. Gene Ther (2012) 1.12
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res (2014) 1.06
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines. Cancers (Basel) (2011) 0.99
Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98
Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 0.98
Single low-dose cyclophosphamide combined with interleukin-12 gene therapy is superior to a metronomic schedule in inducing immunity against colorectal carcinoma in mice. Oncoimmunology (2012) 0.96
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape. Clin Dev Immunol (2012) 0.92
Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome. Oncoimmunology (2013) 0.91
Vaccines for pancreatic cancer. Cancer J (2012) 0.90
Gut microbiome and anticancer immune response: really hot Sh*t! Cell Death Differ (2014) 0.90
Tregs in infection and vaccinology: heroes or traitors? Microb Biotechnol (2011) 0.89
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8(+) T-cell responses and immune memory. Oncoimmunology (2015) 0.88
Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer. Oncoimmunology (2013) 0.86
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health (2016) 0.85
Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One (2014) 0.84
Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer (2012) 0.84
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett (2012) 0.83
Why has active immunotherapy not worked in lung cancer? Ann Oncol (2015) 0.82
Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol (2012) 0.82
Therapeutic DNA vaccination against colorectal cancer by targeting the MYB oncoprotein. Clin Transl Immunology (2015) 0.82
The Concept of Hormesis in Cancer Therapy - Is Less More? Cureus (2015) 0.82
Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model. Cancer Lett (2014) 0.81
Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? J Cancer (2015) 0.81
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol (2015) 0.79
Brain Tumor Immunotherapy: What have We Learned so Far? Front Oncol (2015) 0.79
Measles to the Rescue: A Review of Oncolytic Measles Virus. Viruses (2016) 0.79
Effect of treatment with cyclophosphamide in low doses upon the onset of delayed type hypersensitivity in mice chronically infected with Trypanosoma cruzi: involvement of heart interstitial dendritic cells. Mem Inst Oswaldo Cruz (2013) 0.78
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Mol Ther Nucleic Acids (2013) 0.78
Immunoregulatory Cell Depletion Improves the Efficacy of Photodynamic Therapy-Generated Cancer Vaccines. Int J Mol Sci (2015) 0.77
The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell (2012) 0.77
Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles. Viruses (2015) 0.77
Nanocarrier-based immunotherapy in cancer management and research. Immunotargets Ther (2014) 0.76
Toward maximizing immunotherapy in metastatic castration-resistant prostate cancer - rationale for combinatorial approaches using chemotherapy. Front Oncol (2012) 0.76
From promotion to management: the wide impact of bacteria on cancer and its treatment. Bioessays (2014) 0.76
Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC). Front Oncol (2012) 0.76
Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4+ T cell response against MC38 colon carcinoma. Int J Oncol (2015) 0.75
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer (2016) 0.75
Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. J Immunother Cancer (2015) 0.75
Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells. Crit Rev Immunol (2016) 0.75
Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. Elife (2016) 0.75
Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation. Oncoimmunology (2014) 0.75
Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies. Oncotarget (2016) 0.75
Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy. Front Oncol (2017) 0.75
Contrasting effects of cyclophosphamide on anti-CTLA-4 blockade therapy in two mouse tumor models. Cancer Sci (2017) 0.75
Intratumoral Lentivector-Mediated TGF-β1 Gene Downregulation As a Potent Strategy for Enhancing the Antitumor Effect of Therapy Composed of Cyclophosphamide and Dendritic Cells. Front Immunol (2017) 0.75
Adjuvant IL-7 potentiates adoptive T cell therapy by amplifying and sustaining polyfunctional antitumor CD4+ T cells. Sci Rep (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 46.36
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell (2006) 33.94
TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol (1989) 31.72
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 28.73
Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (2003) 22.89
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Regulatory T cells and immune tolerance. Cell (2008) 18.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med (2006) 13.74
T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity (2007) 13.29
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today (1996) 12.12
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Mouse and human dendritic cell subtypes. Nat Rev Immunol (2002) 10.01
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol (1999) 7.60
Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev (2001) 7.60
Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med (2001) 7.46
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res (2000) 6.42
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 5.78
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res (1999) 5.41
Cancer immunology. N Engl J Med (2008) 5.22
Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (2002) 5.10
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood (2004) 5.02
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood (2009) 4.80
IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem (2007) 4.77
Induction of TH1 and TH2 responses: a key role for the 'natural' immune response? Immunol Today (1992) 4.63
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A (1998) 4.53
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol (2002) 4.32
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest (2010) 3.97
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today (1991) 3.61
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res (2003) 3.44
Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med (2010) 3.43
Decoding cell death signals in inflammation and immunity. Cell (2010) 3.41
T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol (2010) 3.39
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res (2001) 3.32
The CD8+ dendritic cell subset. Immunol Rev (2010) 3.32
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med (2005) 3.22
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
A case for regulatory B cells. J Immunol (2006) 3.20
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.20
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (1980) 3.17
B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer. Ann N Y Acad Sci (2010) 3.07
CD25 is a marker for CD4+ thymocytes that prevent autoimmune diabetes in rats, but peripheral T cells with this function are found in both CD25+ and CD25- subpopulations. J Immunol (2000) 2.98
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol (2001) 2.87
Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res (2005) 2.83
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res (2007) 2.71
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res (2002) 2.69
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67
Inhibitory effects of B cells on antitumor immunity. Cancer Res (2006) 2.57
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
B cells inhibit induction of T cell-dependent tumor immunity. Nat Med (1998) 2.50
Protumor vs antitumor functions of IL-17. J Immunol (2009) 2.38
Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34
Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res (2009) 2.32
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A (1998) 2.29
Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 2.25
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev (2006) 2.00
Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol (2009) 1.91
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur J Immunol (2002) 1.88
T(H)-17: a giant step from T(H)1 and T(H)2. Nat Immunol (2005) 1.86
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Cross-priming. Nat Immunol (2006) 1.78
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood (2010) 1.77
Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ regulatory T cells. J Immunol (2006) 1.75
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol (2005) 1.72
The cell biology of cross-presentation and the role of dendritic cell subsets. Immunol Cell Biol (2008) 1.69
Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol (2007) 1.64
Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer (2005) 1.63
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer. J Urol (1998) 1.57
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood (2000) 1.50
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J Immunother (2007) 1.45
Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res (2001) 1.43
Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol (2010) 1.35
Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma. Clin Transl Sci (2008) 1.33
Exosomes: composition, biogenesis and function. Nat Rev Immunol (2002) 13.99
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Innate or adaptive immunity? The example of natural killer cells. Science (2011) 8.68
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol (2001) 6.20
Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science (2011) 5.62
Malignant effusions and immunogenic tumour-derived exosomes. Lancet (2002) 4.91
The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science (2013) 4.60
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med (2005) 3.64
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity (2013) 3.26
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Natural-killer cells and dendritic cells: "l'union fait la force". Blood (2005) 3.10
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med (2005) 2.93
Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest (2010) 2.89
Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J (2009) 2.72
Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol (2008) 2.70
The IKK complex contributes to the induction of autophagy. EMBO J (2009) 2.41
Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest (2004) 2.40
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res (2010) 2.29
Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol (2004) 2.13
Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res (2010) 2.12
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev (2006) 2.00
Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol (2010) 1.94
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Immunogenic cancer cell death: a key-lock paradigm. Curr Opin Immunol (2008) 1.89
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood (2004) 1.88
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res (2011) 1.88
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res (2007) 1.86
Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J Immunol (2004) 1.86
Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 1.84
Chemotherapy induces ATP release from tumor cells. Cell Cycle (2009) 1.83
Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res (2010) 1.82
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev (2011) 1.76
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res (2010) 1.74
Autophagy and cellular immune responses. Immunity (2013) 1.71
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res (2008) 1.69
Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res (2009) 1.64
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol (2002) 1.63
Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med (2012) 1.63
IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 1.59
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis (2009) 1.56
Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev (2007) 1.55
The potential of exosomes in immunotherapy. Expert Opin Biol Ther (2005) 1.52
Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol (2006) 1.52
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. Eur J Immunol (2005) 1.46
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Cutting edge: crucial role of IL-1 and IL-23 in the innate IL-17 response of peripheral lymph node NK1.1- invariant NKT cells to bacteria. J Immunol (2010) 1.44
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 1.43
Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 1.43
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from "silent" to immunogenic. Cancer Res (2007) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
Dendritic cell derived-exosomes: biology and clinical implementations. J Leukoc Biol (2006) 1.34
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31
Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res (2010) 1.31
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31